These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22098563)

  • 1. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects.
    Zanni MV; Burdo TH; Makimura H; Williams KC; Grinspoon SK
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):385-90. PubMed ID: 22098563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss.
    Fjeldborg K; Christiansen T; Bennetzen M; J Møller H; Pedersen SB; Richelsen B
    Obesity (Silver Spring); 2013 Dec; 21(12):2437-43. PubMed ID: 23512476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163: a biomarker linking macrophages and insulin resistance.
    Parkner T; Sørensen LP; Nielsen AR; Fischer CP; Bibby BM; Nielsen S; Pedersen BK; Møller HJ
    Diabetologia; 2012 Jun; 55(6):1856-62. PubMed ID: 22450890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.
    Semnani-Azad Z; Connelly PW; Johnston LW; Retnakaran R; Harris SB; Zinman B; Hanley AJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e285-94. PubMed ID: 31677389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.
    Reid M; Ma Y; Scherzer R; Price JC; French AL; Plankey MW; Grunfeld C; Tien PC
    AIDS; 2017 Jan; 31(3):385-393. PubMed ID: 28081037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The macrophage activation product sCD163 is associated with a less favourable metabolic profile in prepubertal children.
    Carreras-Badosa G; Prats-Puig A; Diaz-Roldan F; Platero-Gutierrez E; Osiniri I; Riera-Perez E; de Zegher F; Ibañez L; Bassols J; López-Bermejo A
    Pediatr Obes; 2016 Dec; 11(6):543-550. PubMed ID: 26843034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association between Monocyte Surface CD163 and Insulin Resistance in Patients with Type 2 Diabetes.
    Kawarabayashi R; Motoyama K; Nakamura M; Yamazaki Y; Morioka T; Mori K; Fukumoto S; Imanishi Y; Shioi A; Shoji T; Emoto M; Inaba M
    J Diabetes Res; 2017; 2017():6549242. PubMed ID: 29445750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Study of Serum Soluble CD 163 Levels in Women with Polycystic Ovary Syndrome.
    Oruç AS; Yilmaz N; İnal HA; Görkem Ü; Gulsen P; Uğur M; Buyukkagnici U
    Horm Metab Res; 2016 Jun; 48(6):399-403. PubMed ID: 26985764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
    Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
    Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An alternatively activated macrophage marker CD163 in severely obese patients: the influence of very low-calorie diet and bariatric surgery.
    Cinkajzlová A; Lacinová Z; Kloučková J; Kaválková P; Trachta P; Kosák M; Krátký J; Kasalický M; DoleŽalová K; Mráz M; Haluzík M
    Physiol Res; 2017 Sep; 66(4):641-652. PubMed ID: 28406702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD163 is associated with CD163 mRNA expression in adipose tissue and with insulin sensitivity in steady-state condition but not in response to calorie restriction.
    Kračmerová J; Rossmeislová L; Kováčová Z; Klimčáková E; Polák J; Tencerová M; Mališová L; Štich V; Langin D; Šiklová M
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E528-35. PubMed ID: 24423341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble CD163 is associated with body mass index and blood pressure in hypertensive obese Saudi patients.
    Al-Daghri NM; Al-Attas OS; Bindahman LS; Alokail MS; Alkharfy KM; Draz HM; Yakout S; McTernan PG; Sabico S; Chrousos GP
    Eur J Clin Invest; 2012 Nov; 42(11):1221-6. PubMed ID: 22946776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
    Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
    Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased macrophage activation marker soluble CD163 is associated with graft dysfunction and metabolic derangements in renal transplant recipients.
    El Aggan H; Mahmoud S; El Shair H; Elabd H
    Biomed J; 2021 Dec; 44(6 Suppl 2):S179-S189. PubMed ID: 35300946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.
    Grannes H; Ueland T; Simeone P; Liani R; Guagnano MT; Aukrust P; Michelsen AE; Birkeland K; di Castelnuovo A; Cipollone F; Consoli A; Halvorsen B; Gregersen I; Santilli F
    Cardiovasc Diabetol; 2024 Apr; 23(1):146. PubMed ID: 38685051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort.
    Deichgræber P; Witte DR; Møller HJ; Skriver MV; Richelsen B; Jørgensen ME; Johansen NB; Sandbæk A
    Diabetologia; 2016 Nov; 59(11):2467-2476. PubMed ID: 27541014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.
    Burdo TH; Weiffenbach A; Woods SP; Letendre S; Ellis RJ; Williams KC
    AIDS; 2013 Jun; 27(9):1387-95. PubMed ID: 23435298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.